Uniqure NV (QURE)

Currency in USD
20.500
-1.870(-8.36%)
Closed·
20.680+0.180(+0.88%)
·
Earnings results expected in 14 days
QURE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
20.17022.600
52 wk Range
7.76071.500
Key Statistics
Prev. Close
22.37
Open
22.37
Day's Range
20.17-22.6
52 wk Range
7.76-71.5
Volume
2.35M
Average Volume (3m)
2.28M
1-Year Change
44.5698%
Book Value / Share
3.71
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
QURE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
53.384
Upside
+160.41%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period

Uniqure NV News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Uniqure NV Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Compare QURE to Peers and Sector

Metrics to compare
QURE
Peers
Sector
Relationship
P/E Ratio
−5.4x−1.0x−0.5x
PEG Ratio
−0.440.040.00
Price/Book
5.6x3.8x2.6x
Price / LTM Sales
81.1x13.1x3.3x
Upside (Analyst Target)
163.2%196.5%47.0%
Fair Value Upside
Unlock13.1%5.9%Unlock

Analyst Ratings

10 Buy
3 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 53.384
(+160.41% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Barclays
Hold31.00+51.22%-New CoverageJan 28, 2026
H.C. Wainwright
Buy70.00+241.46%-MaintainJan 23, 2026
Cantor Fitzgerald
Buy55.00+168.29%-MaintainJan 14, 2026
Stifel
Buy40.00+95.12%50.00MaintainDec 11, 2025
Mizuho
Buy33.00+60.98%60.00MaintainDec 09, 2025

Earnings

Latest Release
Nov 10, 2025
EPS / Forecast
-1.38 / -0.91
Revenue / Forecast
3.70M / 5.31M
EPS Revisions
Last 90 days

QURE Income Statement

People Also Watch

13.970
VTYX
+0.29%
11.36
BHVN
-1.22%
14.310
FOLD
-0.14%
317.25
PRAX
-4.71%

FAQ

What Is the Uniqure NV (QURE) Stock Price Today?

The Uniqure NV stock price today is 20.500

What Stock Exchange Does Uniqure NV Trade On?

Uniqure NV is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Uniqure NV?

The stock symbol for Uniqure NV is "QURE."

What Is the Uniqure NV Market Cap?

As of today, Uniqure NV market cap is 1.280B.

What Is Uniqure NV's Earnings Per Share (TTM)?

The Uniqure NV EPS (TTM) is -4.34.

When Is the Next Uniqure NV Earnings Date?

Uniqure NV will release its next earnings report on Mar 02, 2026.

From a Technical Analysis Perspective, Is QURE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Uniqure NV Stock Split?

Uniqure NV has split 0 times.

How Many Employees Does Uniqure NV Have?

Uniqure NV has 209 employees.

What is the current trading status of Uniqure NV (QURE)?

As of Feb 16, 2026, Uniqure NV (QURE) is trading at a price of 20.500, with a previous close of 22.370. The stock has fluctuated within a day range of 20.170 to 22.600, while its 52-week range spans from 7.760 to 71.500.

What Is Uniqure NV (QURE) Price Target According to Analysts?

The average 12-month price target for Uniqure NV is USD53.384, with a high estimate of USD97.35717061 and a low estimate of USD30.72420087. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +160.41% Upside potential.

What Is the QURE After Hours Price?

QURE's last after hours stock price is 20.680, the stock has decreased by 0.180, or 0.880%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.